Metastat RGCC
Metastat RGCC is an advanced test to detect specific blood-borne markers that can accurately determine whether a secondary cancerous tumour is likely to develop and its potential location.
During the test, we analyse a sample of a patient’s blood in our state-of-the-art laboratory to analyse, identify and measure circulating tumour cells (CTCs).
Metastat RGCC is suitable for all patients who have received a confirmed cancer diagnosis. The test can accurately detect the development of secondary cancers or tumours and improve personalised cancer treatments.
Purpose of the test
Purpose of the test
Metastat RGCC provides detailed and accurate information about whether a primary cancer is likely to spread in the body and its potential location.
Studies have established that when cancer cells break off from the primary tumour and begin to travel around the body, they express specific genes, proteins, or other markers. These markers vary according to the location of the tumour.
The innovative test can identify specific markers detected on organs and parts of the body, such as the lung, brain, liver, and bones. It is highly sensitive and accurate. The information provided can be used to provide more personalised and targeted therapies and treatments for patients.
Useful information
Useful information
The Metastat RGCC test analyses a patient’s blood sample in two ways:
- Time PCR, which detects the levels of specific marker genes
- Flow cytometry, which identifies the protein levels produced by these genes
The results of Metastat RGCC are compared to a control sample. The results are provided in the format below.
Metastat RGCC requires 7-10ml of whole (peripheral) blood, to be sent an immobilising liquid in a 10ml volume Falcon tube provided by RGCC.
Support and training
Support and training
At RGCC, we provide ongoing training and support for clinicians on how to conduct tests and interpret the results for patients. If you would like more information on the Metastat RGCC test, then get in touch today.